PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT) - Trial NCT06390709
Access comprehensive clinical trial information for NCT06390709 through Pure Global AI's free database. This phase not specified trial is sponsored by Scipher Medicine and is currently Recruiting. The study focuses on Rheumatoid Arthritis. Target enrollment is 1100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Scipher Medicine
Timeline & Enrollment
N/A
Apr 08, 2024
Dec 31, 2025
Primary Outcome
The rate of MSRC to predict the patients response
Summary
Prospective, multi-center-observational study conducted within the US, collecting patient
 samples for research and development to train, test, and validate precision medicine
 classifiers. These molecular signature response classifiers (MSRC) aim to predict response
 status to JAK, T-cell, and IL-6 inhibitor therapies in patients with rheumatoid arthritis
 (RA).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06390709
Non-Device Trial